局部晚期非小细胞肺癌的系统治疗与放疗策略
本文综述局部晚期非小细胞肺癌治疗格局的变化:同步放化疗后巩固免疫治疗已成为新标准,5年生存率显著改善;但多数患者仍出现疾病进展,亟需明确进展后治疗、驱动基因突变患者最佳方案,并优化放疗技术以减少毒性、探索循环肿瘤DNA监测。
要点
- 同步放化疗后巩固免疫治疗已成为局部晚期非小细胞肺癌的新标准治疗。
- 该方案使5年生存率显著改善,但多数患者最终仍出现疾病进展。
- 未来方向包括同步免疫治疗、联合其他药物、优化放疗技术及循环肿瘤DNA监测。
核心结论
- 同步放化疗后巩固免疫治疗已成为局部晚期非小细胞肺癌的新标准治疗,5年生存率显著改善,但多数患者最终仍出现疾病进展,仍需进一步改善疗效。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 同步放化疗后巩固免疫治疗使局部晚期非小细胞肺癌的5年生存率显著改善。
- 尽管上述治疗取得进展,多数患者最终仍出现疾病进展。
- 针对同步放化疗及免疫治疗后出现疾病进展的患者,以及驱动基因突变患者的最佳治疗,仍存在未满足的临床需求。
关键数值与推荐
- 同步放化疗后巩固免疫治疗已成为局部晚期非小细胞肺癌的新标准治疗。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment for locally advanced non-small-cell lung cancer has changed dramatically over the past several years, with consolidative immunotherapy after concurrent chemoradiation becoming the new standard of care. Five-year survival outcomes have substantially improved with this approach. Despite these advances, further improvements are needed as the majority of patients ultimately develop progression of disease. The next-generation immunotherapy trials are currently being conducted that include approaches such as concurrent immunotherapy and addition of other therapeutic agents in the concurrent and consolidative settings. Specific unmet needs continue to exist for patients who develop disease progression after concurrent chemoradiation and immunotherapy, as well as defining the best treatment for patients with driver mutations. Future directions also include refinement of radiation techniques to reduce toxicities as much as possible, as well as the use of circulating tumor DNA in the surveillance setting. The current scientific landscape shows promising approaches that may further improve outcomes for patients with locally advanced non-small-cell lung cancer.
引用
- Higgins KA, Puri S, Gray JE, et al. Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 34985931. doi:10.1200/JCO.21.01707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。